CD274 and cancer: Furthermore, EOC treatments targeting cancer cells have changed dramatically in recent years with the advent of molecularly targeted drugs, such as poly ADP-ribose polymerase (PARP) inhibitors, bevacizumab, and immunological checkpoint inhibitors, such as anti-programmed death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) [141], based on genetic profiling and platinum resistance [142].